Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: misfiled who wrote (55246)	8/10/1999 12:42:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 120523

ARTC-comments from BBRS SAN FRANCISCO, July 23 /PRNewswire/ -- The following is being issued by BancBoston Robertson Stephens, a member of the National Association of Securities Dealers, CRD number 41271: BancBoston Robertson Stephens senior medical device and medical technology analyst Wade H. King, M.D., today commented on ArthroCare's (Nasdaq: ARTC - news) strong-second-quarter-results. ArthroCare, headquartered in Sunnyvale, Calif., is a developer of innovative-radio-frequency devices for use in a variety of clinical applications, including arthroscopy and cosmetic and ENT surgery. ''We are reaffirming our Buy rating on ArthroCare, following the company's announcement of strong-second-quarter 1999 earnings,'' said King. ''The company reported total revenue of $12.2 million, versus our $11.9 million projection. ArthroCare's earnings-per-share came in at $0.14, $0.02 ahead of our $0.12 estimate. In addition, fully taxed earnings-per-share was $0.08, matching our fully taxed projection.'' ''We have revised our model slightly, to reflect incrementally higher product sales and license fees, offset by a reduction in gross margin,'' said King. ''Our earnings-per-share estimates remain unchanged.''